After 12 years of research, Boryung Pharmaceutical succeeded in developing the first domestic hypertension drug, ‘Kanarb’. By independently carrying out all the necessary steps – candidate material excavation, raw material synthesis, formulation research, a non-clinical trial, and clinical trial phases one, two and three – Boryung Pharmaceutical has established our very own capability for drug development.
Boryung Pharmaceutical was established based on its drug development capabilities. We are expanding our scope of research into a variety of areas to develop drugs for cancer treatment, antibiotics, NCE(New Chemical Entity) and gene therapy that focuses on cardiovascular and other major diseases, vaccines and other biopharmaceuticals. We are particularly focused on the development of the Kanarb Value-Up Pipeline.
In addition, we are focusing on the research and development of new API(Active Pharmaceutical Ingredient) products aimed at the globalization of API.